HLS TherapeuticsFRA:74D -3.97%63 EV-to-FCF is 7.08 as of Jul. 04, 2026, which is 32% below its 10-year median of 10.36. GuruFocus rates FRA:74D with a GF Score™ of 63/100 and a GF Value™ of €2.61 (Fairly Valued). The stock has 4 warning signs investors should review. Among 562 Drug Manufacturers companies, HLS Therapeutics ranks better than 84.52% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, HLS Therapeutics's Enterprise Value is €109.00 Mil.
HLS Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €15.39 Mil. Therefore, HLS Therapeutics's EV-to-FCF for today is 7.08.
The historical rank and industry rank for HLS Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:74D'
s EV-to-FCF Range Over the Past 10 Years
Min: -36.19 Med: 10.36 Max: 481.2
Current: 7.09
During the past 13 years, the highest EV-to-FCF of HLS Therapeutics was 481.20. The lowest was -36.19. And the median was 10.36.
FRA:74D's EV-to-FCF is ranked better than 84.52% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.525
vs FRA:74D: 7.09
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HLS Therapeutics's PE Ratio (TTM) for today is calculated as:
HLS Therapeutics's share price for today is €2.42.
HLS Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.275.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
HLS Therapeutics EV-to-FCF Related Terms
HLS Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's EV-to-FCF falls into.
HLS Therapeutics's current Enterprise Value is €109.00 Mil.
HLS Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €15.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics (FRA:74D) has a EV-to-FCF of 7.08 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on HLS Therapeutics and its competitors. This is 32% below median its historical median of 10.36. According to the industry distribution chart, HLS Therapeutics ranks #87 out of 562 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is HLS Therapeutics' EV-to-FCF too high?
HLS Therapeutics' current EV-to-FCF of 7.08 is 32% below median its 10-year median of 10.36. The Drug Manufacturers industry median EV-to-FCF is 20.53. HLS Therapeutics' value of 7.08 is 65.5% below this industry median. Based on the distribution chart, HLS Therapeutics ranks #87 out of 562 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HLS Therapeutics has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #87 out of 562 companies for EV-to-FCF. This places HLS Therapeutics in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.53. HLS Therapeutics' value of 7.08 is 65.5% below this benchmark. While the company's 10-year median is 10.36 vs. the industry median of 20.53, HLS Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.53, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HLS Therapeutics's current EV-to-FCF of 7.08 is 65.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current EV-to-FCF is 7.08, which is 32% below median its own 10-year median of 10.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (FRA:74D) is currently considered Fairly Valued. The stock's GF Value™ is €2.61, compared to a current price of €2.42 — trading 7.3% below its estimated fair value. The current EV-to-FCF is 7.08, which is 32% below median its 10-year median of 10.36 and 65.5% below the Drug Manufacturers industry median of 20.53. HLS Therapeutics' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For HLS Therapeutics (FRA:74D), the current EV-to-FCF is 7.08 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (FRA:74D) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of €2.42 is trading 7.3% below its estimated GF Value™ of €2.61.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for FRA:74D:
EV-to-FCF: 7.08 (32% below median its 10-year median of 10.36)
GF Value™: €2.61 vs. price of €2.42 (7.3% below fair value)
Industry Position: 65.5% below the Drug Manufacturers median (#87 of 562)
No single metric tells the full story. See the FRA:74D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
63GF Score
Get the complete analysis for FRA:74D
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:74D has been successfully added to your 
